Compare LyondellBasell Industries NV (LYB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Tango Therapeutics Inc. — how do they compare? LyondellBasell Industries NV trades at $61.68 (market cap $19.76B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: LyondellBasell Industries NV is far larger — about 5.3× Tango Therapeutics Inc.'s market cap, and LyondellBasell Industries NV pays a 4.51% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 88 Days and Tango Therapeutics Inc. for 0 Days on average.
| LYB | TNGX | |
|---|---|---|
Market Cap | $19.76B | $3.74B |
Volume | 2,519,506 | 3,438,781 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $32.90 |
52-Week Low | $42.28 | $7.50 |
Typical Hold Time | 88 Days | 0 Days |
Enterprise Value | $31.35B | $2.76B |
Dividend Yield | 4.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.01, up 1.01% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue declined to $30.15B in 2025, with a net loss of $745M, though Q2 2026 EPS beat expectations at $4.30. The company maintains a dividend payout, with a consensus analyst price target of $68.56. Cash flow from operations improved to $2.26B in 2025, but debt-to-asset ratio rose to 38.18%.
Outlook is mixed: analyst consensus is evenly split between Buy and Hold, with potential upside to the price target, but risks include declining revenue, negative profit margins, and high debt. Recent news highlights dividend sustainability concerns in the chemical sector, though some analysts see earnings recovery potential.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
